Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855695 · ClinicalTrials.gov registry record · Phase 1
Avo In R/R And Previously Untreated MCL
A Phase 1 study of Mantle Cell Lymphoma and Refractory Lymphoma, sponsored by Austin I Kim.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 3
- Study locations
NCT04855695: Recruiting Phase 1 study of Mantle Cell Lymphoma and Refractory Lymphoma, sponsored by Austin I Kim.
NCT04855695 is a Phase 1 study of Mantle Cell Lymphoma and Refractory Lymphoma that is actively recruiting participants, run by Austin I Kim. The registered enrollment target is 72 participants, below the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (30% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04855695, a Phase 1 study of Mantle Cell Lymphoma and Refractory Lymphoma, is actively recruiting participants, sponsored by Austin I Kim.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 3
- Study locations
Study Summary
This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzumab
Primary Outcome
The RP2D will be defined as the highest dose level for which there are no more than 1/6 DLTs observed.
Conditions Studied
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Acalabrutinib
Study Locations (3)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-07-02 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 1 |
What NCT04855695 shows while recruiting
NCT04855695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 103-participant average among 102 other Mantle Cell Lymphoma trials with a reported enrollment target (30% lower).
The record links to 2 conditions, with Mantle Cell Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT04855695 reports a single indexed study location in Massachusetts, Illinois.
Frequently Asked Questions
What is clinical trial NCT04855695 about?
NCT04855695 is a clinical study titled "Avo In R/R And Previously Untreated MCL". This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obin...
What is the current status of trial NCT04855695?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-07-02. Estimated completion is 2027-12-31.
What conditions does trial NCT04855695 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma, Refractory Lymphoma.
What interventions are being tested in trial NCT04855695?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Acalabrutinib (DRUG).
Who is sponsoring clinical trial NCT04855695?
This trial is sponsored by Austin I Kim, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04855695 being conducted?
This trial has 3 study locations across Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04855695's enrollment target sits among peer trials
72 32nd of 102 higher than 71 of 102 other Mantle Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
RECRUITING · Phase 1
-
A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma
RECRUITING · Phase 1
-
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RECRUITING · Phase 1
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI